Medicare Drug Plan Premiums Could Jump Sharply for 2027, New KFF Report Warns
Medicare open enrollment runs through December 7, and a KFF analysis released October 30 warns that the average standalone drug plan premium could jump about 50 percent for 2027 for people who keep their current plan. KFF also found no standalone plan will offer a zero dollar premium next year, so comparing options before the deadline matters more than usual.
Medicare's yearly window to review coverage is open now and closes December 7. A new report gives older Americans a strong reason to compare drug plans this year. On Friday, October 30, the health research group KFF published an analysis showing that many standalone Medicare drug plans will cost more in 2027.
KFF found that the average premium for standalone Part D prescription drug plans could climb about 50 percent, from about 34 dollars a month in 2026 to about 51 dollars a month in 2027, for people who keep their current plan. KFF said about 76 percent of enrollees who do not get low income help, roughly three in four, would pay a higher premium in 2027 if they make no changes during open enrollment.
The report also found that no standalone drug plan will offer a zero dollar premium in 2027. KFF said about 4 million people who pay nothing today would have to start paying something. Among the eight plans sold nationwide, KFF projected that average monthly premiums will range from about 6 dollars a month to about 204 dollars a month, so the plan you pick makes a big difference.
KFF pointed to a federal program that is ending as one reason for the higher prices. A temporary program called the Part D Premium Stabilization Demonstration, which helped hold down standalone drug plan premiums, is set to end for 2027 rather than continue another year, and KFF said that choice likely pushed premiums higher. KFF noted the real average could end up lower than 51 dollars if many people shop around and switch to cheaper plans.
Other costs are moving too. KFF said the most a standalone plan can charge as a yearly deductible rises to 700 dollars in 2027, up from 615 dollars in 2026, and the average deductible is set to climb as well. For comparison, KFF said drug coverage inside many Medicare Advantage plans is projected to average only about 9 dollars a month.
The practical step is to read any notice your plan mailed you and compare your options before December 7. Check whether your doctors, hospitals, and medicines are still covered, and look past the premium at other costs. Think twice before dropping drug coverage, because a long gap can add a lasting late penalty. Free, unbiased help is available at Medicare.gov, by calling 1-800-MEDICARE, or through your State Health Insurance Assistance Program, known as SHIP.
Go Deeper
When does Medicare open enrollment end?
December 7, with any changes you make starting January 1.
What did the new report find?
KFF projects the average standalone Part D premium could rise about 50 percent in 2027, from about 34 to about 51 dollars a month, for people who keep their current plan.
Will there be any zero dollar drug plans?
No. KFF found no standalone drug plan will offer a zero dollar premium in 2027, which affects about 4 million people who pay nothing now.
Why are premiums rising?
KFF said a temporary federal program that held premiums down, the Part D Premium Stabilization Demonstration, is ending for 2027 rather than continuing another year.
What should I do?
Compare plans before December 7, look past the premium at other costs, and get free help at Medicare.gov, 1-800-MEDICARE, or your state SHIP program.
More health
health50+Researchers Identify Potential Driver of Aging in Immune Cells
A study found that immune cells losing their ability to clear away damaged cells may contribute to aging. Blocking a specific receptor in mice helped
Sep 27
health50+Study Finds Dementia Risk Factors in People Over 90
A recent study examined dementia risk in people over 90 and found that sex, race, and genetics play a significant role. The study also identified indi
Sep 27
health50+Ozempic Shows Promise in Slowing Aging in Mice
Scientists have found that semaglutide, the active ingredient in Ozempic, may help slow aging in older healthy mice. The drug improved memory, muscle
Sep 27